Parallax Volatility Advisers’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Parallax Volatility Advisers’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-53,243	Closed	-$200K	–	4032
2018 Q2	$200K	Buy	+53,243	New	+$259K	﹤0.01%	1404
2018 Q1	–	Sell	-13,608	Closed	-$63K	–	5177
2017 Q4	$63K	Buy	+13,608	New	+$75K	﹤0.01%	3092
2016 Q1	–	Sell	-32,066	Closed	-$162K	–	4152
2015 Q4	$162K	Buy	+32,066	New	+$152K	﹤0.01%	1959
2015 Q3	–	Sell	-47,962	Closed	-$321K	–	4716
2015 Q2	$479K	Buy	+47,962	New	+$514K	﹤0.01%	1648

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PIMJS

PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's KERX Position: Q3 2018 in Review

Parallax Volatility Advisers sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 53,243 shares — an estimated $200K sold.

Parallax Volatility Advisers first reported a position in KERX in Q2 2015 and held it in 4 quarters. The position peaked at $479K in Q2 2015. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

Parallax Volatility Advisers reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
Parallax Volatility Advisers sold 53,243 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $200K.
Parallax Volatility Advisers first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 4 quarters.
Parallax Volatility Advisers's Keryx Biopharmaceuticals Inc position peaked at $479K in Q2 2015.
123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Parallax Volatility Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.